Oxford Biomedica PLC 2020 AR2
The report highlights Oxford Biomedica's pivotal role in manufacturing the Oxford AstraZeneca COVID-19 vaccine, scaling up production to 1000L in under nine months. Financially, the Group achieved a 37% revenue increase to £87.7 million, driven by a 45% growth in bioprocessing and commercial development revenues. The company successfully completed a £38.3 million equity fundraising to expand its facilities, including the Oxbox manufacturing site. On the ESG front, Oxford Biomedica transitioned to green energy providers, achieved zero major injuries, and established a Workforce Engagement Panel to enhance employee relations.
Company: Oxford Biomedica PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2020
Type: AR2
Pages: 192
Back to company
Oxford Biomedica PLC
Annual Report And Accounts
The report highlights Oxford Biomedica's pivotal role in manufacturing the Oxford AstraZeneca COVID-19 vaccine, scaling up production to 1000L in under nine months. Financially, the Group achieved a 37% revenue increase to £87.7 million, driven by a 45% growth in bioprocessing and commercial development revenues. The company successfully completed a £38.3 million equity fundraising to expand its facilities, including the Oxbox manufacturing site. On the ESG front, Oxford Biomedica transitioned to green energy providers, achieved zero major injuries, and established a Workforce Engagement Panel to enhance employee relations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Women on Board
Women in Management
Workplace Fatalities
Employees